Cost Modeling for AAV Manufacturing with TESSA

This technical report presents a detailed analysis of cost modeling for recombinant adeno-associated virus (rAAV) manufacturing using the TESSA® platform. The report outlines the complexities involved in rAAV production, particularly the challenges associated with adenoviral helper functions and the risks of contamination. It describes how TESSA® provides a solution by supplying the necessary components for rAAV production in a manner that eliminates the need for costly plasmids and stable cell lines. The report details the comparative yields of rAAV using different methodologies, highlighting the significant cost reductions achieved with TESSA® compared to traditional plasmid transfection methods. It also discusses the scalability of AAV production and the implications for patient access to AAV-based therapies, emphasizing the potential of TESSA® to transform manufacturing processes. The findings indicate that TESSA® can lead to substantial reductions in cost per dose across various serotypes, making AAV therapies more affordable and accessible to healthcare providers and patients.